NASDAQ : ATRA
Atara Biotherapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.01 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 80.40M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 80.40M |
| Enterprise Value | 80.41M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 10.04M |
| Shares Outstanding | 10.04M |
| Shares Change (YoY) | +36.26% |
| Shares Change (QoQ) | +6.76% |
| Owned by Insiders (%) | 3.68% |
| Owned by Institutions (%) | 21.62% |
| Float | 4.62M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 26.92 |
| PS Ratio | 12.98 |
| Forward PS | 2.38 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 12.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.98 |
| Quick Ratio | 1.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.96 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.14% |
| Return on Invested Capital (ROIC) | -78.42% |
| Return on Capital Employed (ROCE) | -78.90% |
| Weighted Average Cost of Capital (WACC) | 7.82% |
| Revenue Per Employee | $619,400 |
| Profits Per Employee | -$1.67M |
| Employee Count | 10 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 29,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -43.03% |
| 50-Day Moving Average | 9.20 |
| 200-Day Moving Average | 7.68 |
| Relative Strength Index (RSI) | 37.55 |
| Average Volume (20 Days) | 25,935 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 350,260 |
| Short Previous Month | 321,792 |
| Short % of Shares Out | 3.49% |
| Short % of Float | 7.58% |
| Short Ratio (days to cover) | 8.52 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.19M |
| Gross Profit | 4.66M |
| Operating Income | -11.19M |
| Pretax Income | -16.66M |
| Net Income | -16.69M |
| EBITDA | -11.06M |
| EBIT | -11.19M |
| Loss Per Share | -$1.19 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.87M |
| Total Debt | 9.88M |
| Net Cash | -6,000 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | -37.00M |
| Book Value Per Share | -3.92 |
| Working Capital | 6.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -21.90M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 128,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -21.90M |
| FCF Per Share | -$2.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.27% |
| Operating Margin | -180.59% |
| Pretax Margin | -268.95% |
| Profit Margin | -269.42% |
| EBITDA Margin | -178.53% |
| EBIT Margin | -180.59% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.26% |
| Shareholder Yield | n/a |
| Earnings Yield | -14.84% |
| FCF Yield | -27.23% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.67 |
| Price Target Difference | 70.66% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -42.76% |
| EPS Growth Forecast (3Y) | -41.86% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -135.53 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |